Angiostatin generation by human tumor cell lines: Involvement of plasminogen activators

International Journal of Cancer

Volumn 86, Issue 6, 2000, Pages 760-767

  Westphal, Johan R ^a   Van't Hullenaar, Rianne ^a   Geurts Moespot, Anneke ^a   Sweep, Fred C J G ^a   Verheijen, Jan H ^b   Bussemakers, Marion M G ^a   Askaa, Jon ^c   Clemmensen, Inge ^c   Eggermont, Alexander A M ^d   Ruiter, Dirk J ^a   De Waal, Robert M W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c Dako   (Denmark)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; PLASMINOGEN ACTIVATOR;

ANGIOGENESIS; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; COLON CARCINOMA; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MELANOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANGIOSTATINS; CULTURE MEDIA, CONDITIONED; ENDOPEPTIDASES; FEMALE; HUMANS; MALE; NEOPLASMS; PEPTIDE FRAGMENTS; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0034660009     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000615)86:6<760::AID-IJC2>3.0.CO;2-4     Document Type: Article

References (36)

1. BANTEL-SCHAAL, U., Growth properties of a human melanoma cell line are altered by adeno-associated parvovirus type 2. Int. J. Cancer. 60, 269-274 (1995).
2. BOEHM, T., FOLKMAN, J., BROWDER, T. and O'REILLY, M.S., Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390, 404-407 (1998).
3. CANEVARI, S., ORLANDI, R., RIPAMONTI, M., TAGLIABUE, E., AGUANNO, S., MIOTTI, S., MENARD, S. and COLNAGHI, M.I., Ricin A chain conjugated with monoclonal antibodies selectively killing human carcinoma cells in vitro. J. nat. Cancer Inst., 75, 831-839 (1985).
4. CAO, Y., CHEN, A., AN, S.S.A., JI, R.-W., DAVIDSON, D. and LLINÁS, M., Kringle 5 of plasminogen is a novel inhibitor of endothelial-cell growth. J. biol. Chem., 272, 22924-22828 (1997).
5. CORNELIUS, L.A., NEHRING, L.C., HARDING, E., BOLANOWSKI, M., WELGUS, H.G., KOBAYASHI, D.K., PIERCE, R.A. and SHAPIRO, S.D., Matrix metalloproteinases generate angiostatin: effects on neovascularization. J. Immunol., 161, 6845-6952 (1998).
6. DEUTSCH, D.G. and MERTZ, E.T., Plasminogen: purification from human plasma by affinity chromatography. Science, 170, 1095-1096 (1970).
7. DONG, Z., KUMAR, R., YANG, X. and FIDLER, I.J., Macrophage-derived metallo-elastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell, 88, 801-810 (1997).
8. DONG, Z., YONEDA, J., KUMAR, R. and FIDLER, I.J., Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage-colony-stimulating factor. J. exp. Med., 188, 755-763 (1998).
9. FIDLER, I.J. and ELLIS, L.M., The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 79, 185-188 (1994).
10. FOLKMAN, J., Tumor angiogenesis: therapeutic implications. New Engl. J. Med., 285, 1182-1186 (1971).
11. FOLKMAN, J., Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med., 1, 27-31 (1995).
12. GATELY, S. and 12 OTHERS, Human prostate-carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res., 56, 4887-4890 (1996).
13. GATELY, S. and 12 OTHERS, The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. nat. Acad. Sci. (Wash.), 94, 10868-10872 (1997).
14. GOLDBERG, M.A., GLASS, G.A., CUNNINGHAM, J.M. and BUNN, H.F., The regulated expression of erythropoietin by two human hepatoma cell lines. Proc. nat. Acad. Sci. (Wash.). 84, 7972-7976 (1987).
15. GREBENSCHIKOV, N., GEURTS-MOESPOT, A., DE WITTE, H., HEUVEL, J., LEAKE, R., SWEEP, F. and BENRAAD, T., A sensitive and robust assay for urokinase- and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-I) in breast-tumor cytosols. Int. J. biol. Markers, 12, 6-14 (1997).
16. HERLYN, D., LIDOULOS, D., JENSEN, P.J., PARMITER, A., BAIRD, J., HOTTA, H., ADACHI, K., ROSS, A.H., JAMBROSIC, J., KOPROWSKI, H. and HERLYN, M., In vitro properties of human melanoma cells metastatic in nude mice. Cancer Res., 50, 2296-2302 (1990).
17. HOFMANN, U.B., WESTPHAL, J.R., WAAS, E.T., ZENDMAN, A.J.W., CORNELISSEN, I.M.A.H., RUITER, D.J. and VAN MUIJEN, G.N.P., Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Brit. J. Cancer, 81, 774-782 (1999).
18. JI, R.-W., BARRIENTOS, L.G., LLINÁS, M., GRAY, H., VILLARREAL, X., DEFORD, M.E., CASTELLINO, F.J., KRAMER, R.A. and TRAIL, P.A., Selective inhibition by kringle 5 of human plasminogen on endothelial-cell migration, an important process in angiogenesis. Biochem. biophys. Res. Commun., 247, 414-419 (1998).
19. KERBEL, R.S., A cancer therapy resistant to resistance. Nature (Lond.), 390, 335-336 (1997).
20. LETHE, B., VAN DER BRUGGEN, P., BRASSEUR, F. and BOON, T., MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Res., 7, S83-S88 (1997).
21. LIJNEN, H.R., UGWU, F., BINI, A. and COLLEN, D., Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry, 37, 4699-4702 (1998).
22. LU, H., DHANABAL, M., VOLK, R., WATERMAN, M.J.F., RAMCHANDRAN, R., KNEBELMANN, B., SEGAL, M. and SUKHATME, V.P., Kringle 5 causes cell-cycle arrest and apoptosis of endothclial cells. Biochem. biophys. Res. Commun., 668-673 (1999).
23. LUYTEN, G.P., NAUS, N.C., MOOY, C.M., HAGEMEIER, A., KAN-MITCHELL, J., VAN DRUNEN, E., VUZEVSKI, V., DE JONG, P.T. and LUIDER, T.M., Establishment and characterization of primary and metastatic uveal-melanoma cell lines. Int. J. Cancer, 66, 380-387 (1996).
24. MÜLLER, B.M., ROMERDAHL, C.A., TRENT, J.M. and REISFELD, R.A., Suppression of spontaneous melanoma metastasis in SCID mice with an antibody to the epidermal-growth-factor receptor. Cancer Res., 51, 2193-2198 (1991).
25. O'MAHONY, C.A., SEIDEL, A., ALBO, D., CHANG, H., TUSZYNSKI, G.P. and BERGER, D.H., Angiostatin generation by human pancreatic cancer. J. surg. Res., 77, 55-58 (1998).
26. O'REILLY, M.S., BOEHM, T., SHING, Y., FUKAI, N., VASIOS, G., LANE, W.S., FLYNN, E., BIRKHEAD, J.R., OLSEN, B.R. and FOLKMAN, J., Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-285 (1997).
27. O'REILLY, M.S., HOLMGREN, L., CHEN, C. and FOLKMAN, J., Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med., 2, 689-692 (1996).
28. O'REILLY, M.S., HOLMGREN, L., SHING, Y., CHEN, C., ROSENTHAL, R.A., MOSES, M., LANE, W.S., CAO, Y., SAGE, E.H. and FOLKMAN, J., Angiostalin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 315-328 (1994).
29. PARANGI, S., O'REILLY, M.S., CHRISTOFORI, G., HOLMGREN, L., GROSVELD, J., FOLKMAN, J. and HANAHAN, D., Anti-angiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. nat. Acad. Sci. (Wash.), 93, 2002-2007 (1996).
30. PATTERSON, B.C. and SANG, Q.A., Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type-IV collagenase (MMP-9). J. biol. Chem. 272, 28823-28825 (1997).
31. VAN ELSAS, A., AARNOUDSE, C., VAN DER MINNE, C.E., VAN DER SPEK, C.W., BROUWENSTIJN, N., OSANTO, S. and SCHRIER, P.I., Transfection of IL-2 augments CTL response to human melanoma cells in vitro: immunological characterization of a melanoma vaccine. J. Immunother., 20, 343-353 (1997).
32. VAN MUIJEN, G.N.P., CORNELISSEN, L.M.A.H., JANSEN, C.F.J., FIGDOR, C.G., JOHNSON, J.P., BRÖCKER, E.-B. and RUITER, D.J., Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice. Clin. exp. Metastasis, 9, 259-272 (1991a).
33. VAN MUIJEN, G.N.P., JANSEN, C.F.J., CORNELISSEN, I.M.A.H., SMEETS, D.F.C.M., BECK, J.L.M. and RUITER, D.J., Establishment and characterization of a human melanoma cell line (MV3) which is highly metastatic in nude mice. Int. J. Cancer. 48, 85-91 (1991b).
34. WEIDNER, N., Intratumor microvessel density as a prognostic factor in cancer. Amer. J. Pathol., 147, 9-19 (1995).
35. WESTPHAL, J.R., VAN'T HULLENAAR, R., PEEK, R., WILLEMS, R.W., CRICKARD, K., CRICKARD, U., ASKAA, J., CLEMMENSEN, I., RUITER, D.J. and DE WAAL, R.M.W., Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF, and angiostatin in relation to vascular density of xenografts in vivo. Int. J. Cancer, 86, 768-776 (2000).
36. WESTPHAL, J.R., VAN'T HULLENAAR, R.G.M., VAN DER LAAK, J.A.W.M., CORNELISSEN, L.M.H.A., SCHALKWIJK, C.J.M., VAN MUIJEN, G.N.P., WESSELING, P., DE WILDE, P.C.M., RUITER, D.J. and DE WAAL, R.M.W., Vascular density in melanoma xenografts correlates with vascular-permeability-factor expression but not with metastatic potential. Brit. J. Cancer. 76, 561-570 (1997).